You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 13, 2024

KYNMOBI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Kynmobi patents expire, and what generic alternatives are available?

Kynmobi is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are fourteen patents protecting this drug.

This drug has two hundred and fifty-four patent family members in twenty-six countries.

The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Kynmobi

A generic version of KYNMOBI was approved as apomorphine hydrochloride by SAGE CHEMS on February 23rd, 2022.

  Sign Up

Summary for KYNMOBI
Drug patent expirations by year for KYNMOBI
Drug Prices for KYNMOBI

See drug prices for KYNMOBI

Recent Clinical Trials for KYNMOBI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
SunovionPhase 4
William Ondo, MDPhase 4

See all KYNMOBI clinical trials

US Patents and Regulatory Information for KYNMOBI

KYNMOBI is protected by fourteen US patents.

Patents protecting KYNMOBI

Sublingual apomorphine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual and buccal film compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual films
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual films
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Sublingual films
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Sublingual films
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-005 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for KYNMOBI

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 ⤷  Sign Up ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 ⤷  Sign Up ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 ⤷  Sign Up ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 ⤷  Sign Up ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-001 May 21, 2020 ⤷  Sign Up ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-001 May 21, 2020 ⤷  Sign Up ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for KYNMOBI

When does loss-of-exclusivity occur for KYNMOBI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 11343429
Estimated Expiration: ⤷  Sign Up

Patent: 17200331
Estimated Expiration: ⤷  Sign Up

Patent: 19200138
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2013015204
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 21756
Estimated Expiration: ⤷  Sign Up

Patent: 15370
Estimated Expiration: ⤷  Sign Up

Patent: 15378
Estimated Expiration: ⤷  Sign Up

Patent: 16942
Estimated Expiration: ⤷  Sign Up

China

Patent: 3476372
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 22988
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 51357
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 1156
Estimated Expiration: ⤷  Sign Up

Patent: 1390855
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 51357
Estimated Expiration: ⤷  Sign Up

Patent: 35988
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 93969
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 49349
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 5936
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 86195
Estimated Expiration: ⤷  Sign Up

Patent: 13545824
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 13006911
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 2686
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 51357
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 51357
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1304740
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1890317
Estimated Expiration: ⤷  Sign Up

Patent: 1946774
Estimated Expiration: ⤷  Sign Up

Patent: 2025238
Estimated Expiration: ⤷  Sign Up

Patent: 2161392
Estimated Expiration: ⤷  Sign Up

Patent: 140043051
Estimated Expiration: ⤷  Sign Up

Patent: 180094143
Estimated Expiration: ⤷  Sign Up

Patent: 190015597
Estimated Expiration: ⤷  Sign Up

Patent: 190109598
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 91715
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KYNMOBI around the world.

Country Patent Number Title Estimated Expiration
Hungary E049349 ⤷  Sign Up
New Zealand 597237 Sublingual apomorphine ⤷  Sign Up
Japan 2015199743 舌下用アポモルフィン (SUBLINGUAL APOMORPHINE) ⤷  Sign Up
South Africa 201507685 SUBLINGUAL AND BUCCAL FILM COMPOSITIONS ⤷  Sign Up
Australia 2017200331 SUBLINGUAL FILMS ⤷  Sign Up
Australia 2002362772 ⤷  Sign Up
Spain 2699077 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.